The revenue for ART-27.13 is expected to reach an annual total of $3 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ART-27.13 Overview
ART-27.13 (NEO-1940, AZD-1940) is under development for the treatment of cancer related anorexia. The drug candidate is a benzimidazole derivative which is administered through oral route. It acts by targeting cannabinoid (CB1) type 1 and type 2 receptor. The drug candidate is a new chemical entity.
It was also under development for the treatment of post-operative pain, multimodal supportive care in weight loss, appetite loss, pain, nausea, vomiting, anxiety, insomnia in cancer patients, nociceptive pain, chronic low back pain and neuropathic pain.
Artelo Biosciences Overview
Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system.
For a complete picture of ART-27.13’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.